The US Patent and Trademark Office (USPTO) has granted a patent to Vistagen’s non-opioid oral product candidate, AV-101 for ...

SOUTH SAN FRANCISCO, Calif. - Vistagen Therapeutics (VTGN), a clinical-stage biopharmaceutical company with a market ...

Vistagen (VTGN) announced that the U.S. Patent and Trademark Office or USPTO, granted a patent to the company for its oral non-opioid product ...

Vistagen (Nasdaq: VTGN), a clinical-stage biopharmaceutical company pioneering neuroscience to deliver groundbreaking therapies for individuals affected by psychiatric and neurological disorders, ...

the availability and scope of applicable patents; fluctuating costs of materials and other resources and services required to conduct Vistagen’s ongoing and/or planned clinical and nonclinical ...

Vistagen (NASDAQ:VTGN) reported positive results from a Phase 2a pilot study of its drug candidate PH15 in the improvement of psychomotor impairment caused by mental fatigue. The drug developer ...

Vistagen (VTGN) announced enrollment of the first subject in a repeat dose study of fasedienol, its investigational neuroactive pherine nasal spray in Phase 3 development for the acute treatment ...

All planned clinical studies in fasedienol U.S. registration-directed Phase 3 program for the acute treatment of social anxiety disorder are underway Vistagen (Nasdaq: VTGN), a late clinical-stage ...

Vistagen, a late clinical-stage company dedicated to pioneering neuroscience based on nose-to-brain neurocircuitry, announced positive results from an exploratory phase 2A study of PH284 in cancer ...